Genomic integrity of human pluripotent stem cells (hPSCs) is essential for research and clinical applications. However, genetic abnormalities can accumulate during hPSC generation and routine culture and following gene editing. Their occurrence should be routinely monitored, but the current assays to assess hPSC genomic integrity are not fully suitable for suchregular screening. To address this issue, we first carried out a large meta-analysis of all hPSC genetic abnormalities reported in more than 100 publications and identified 738 recurrent genetic abnormalities (i.e., overlapping abnormalities found in at least five distinct scientific publications). We then developed a test based on the droplet digital PCR technology that can potentially detect 94.3% of these hPSC recurrent genetic abnormalities in DNA extracted from culture supernatant samples. This test can be used to routinely screen genomic integrity in hPSCs.
Introduction
Human pluripotent stem cells (hPSCs) are stem cells that endlessly selfrenew in vitro and that can differentiate into all adult cell types. Therefore, they are a potentially infinite and physiologically relevant cell material for research (in vitro modeling of human development and diseases) and regenerative medicine/cell therapies. These cells are isolated from discarded human embryos (i.e., human embryonic stem cells; hESCs), or obtained from differentiated cells by cell reprogramming (i.e., human induced pluripotent stem cells; hiPSCs). It is crucial that hPSC genome remains the faithful genetic copy of the cells from which they were derived. However, genetic abnormalities (e.g., karyotype abnormalities) can arise in hPSCs, for instance during cell reprogramming, cell culture, or genome editing . Many of these genetic abnormalities are often recurrent. For instance, gains of chromosome 12 (most frequently 12p), 17 (particularly 17q), 20 or X have been often detected using standard cytogenetic procedures (G-banding) (Lefort et al., 2009 ). Sub-chromosomal abnormalities, such as 20q11.21 amplification, also can be recurrent. The biological significance of such recurrent abnormalities is still discussed, but they might result in a strong selective growth advantage for cultured cells, as already demonstrated for the 20q11.21 amplification (Zhang et al., 2019) . Therefore, it is crucial to carefully catalogue all genetic alterations found in hPSCs and identify the recurrent ones. To this aim, we carried out a meta-analysis of published genetic abnormalities found in hPSCs. We could give a precise definition of recurrent genetic abnormality and then listed all of them in a large dataset. As these recurrent genetic abnormalities are found in specific genomic regions, we developed a focused droplet digital PCR (ddPCR) approach that allowsscreening more than 90% of these recurrent abnormalities in DNA isolated from cell culture supernatant. This method greatly simplifies and therefore encouragesthe regular and systematic hPSCs screening.
Results

Meta-analysis of hPSC genetic abnormalities and identification of a recurrencepattern
To catalogue all genetic abnormalities previously detected in hPSCs using various techniques (karyotyping, fluorescence in situ hybridization, comparative genomic hybridization, microarray-based comparative genomic hybridization, and next generationsequencing, NGS), we selected primary research articlesthat reported genetic abnormalities in hESCs and hiPSCs, and extracted the DNA abnormalitygenomic coordinates as well as the experimental data to characterize these abnormalities. We collected data on 942 cell samples and on 415 750 variants and abnormalities from 104 different studies published between 2004 and 2016 ( Figure 1A -B, and Table   S1 ). The dataset included the major publications on genetic abnormalities in hPSCs during culture and also articles that identified one or several abnormal clones in new hPSC lines. A first global analysisof all listed mutations allowed identifying genome locations where these abnormalities were more frequently localized: trisomy 12 and 12p amplification, 20q11.21 amplification, trisomy 17 and 17q amplification, chromosome 1 amplification, and trisomy X (female cell lines) ( Figure S1A ). Abnormalities that accumulated at a specific genome location (i.e., recurrent abnormalities) weremostly aneuploidy or copy number variations (CNV), in agreement with previous reports. No abnormality smaller than 10 base pairs (bp) displayed a recurrent profile in this large dataset ( Figure S1B ). We also reported 93 translocations and 20 inversions, involving all chromosomes with the exception of chromosome 12, mainly of chromosomes 1 and 17, but without a clear recurrent pattern ( Figure 1C ). As described previously (Bai et al., 2015) , genetic abnormalities were more frequently reported when hPSCs were cultured using enzymatic passaging compared with mechanical passaging ( Figure 1D -E). However, the frequency of abnormalities associated with enzymatic passaging decreased after 15 passages.
In summary, this large meta-analysis of genetic abnormalities in hPSCs confirms the recurrence of large CNVs and chromosomal abnormalities, and provides a large dataset of recurrent abnormalities.
Definition and analysis of recurrent genetic abnormalities
As no quantitative definition of a recurrent hPSC genetic abnormality exists in the literature, we wanted to establish a clear threshold for such events. A recurrent genetic abnormality was therefore defined as a nonpolymorphic variant that overlaps with abnormalities found in other hPSC lines. The recurrence pattern most likely reflects a common functional cause that occurs in different laboratories and in different cell lines . We hypothesized that the abnormalities with the strongest functional impact on hPSC growth would be those that are (1) common to different hPSC lines and (2) found in different culture conditions. We estimated that a genetic abnormality met these two criteria if all/part of the altered sequence overlapped with that of other genetic abnormalities that weredescribed in at least four other distinct scientific publications (thus, at least five articles in total) ( Figure 2A ).To identify recurrent genetic abnormalities based on thesecriteria, we analyzed all variants>10bp that were not polymorphisms (n = 8284). We found that recurrent abnormalities are only CNVs (including chromosomal gain or losses) ( Figure 2B ). By plotting the genomic coordinates of these 738 recurrent abnormalities, we found that they were mainly localized in known hotspots, such as chromosome 1, 12, 17q, 20q11.21 or X ( Figure   2C ). Conversely, there were no recurrent abnormalities in chromosome 2, 4, 10 or 21.
We then investigated the nature of these hotspot regions (Figure 2A ) (Table 1 , lists the ten more frequent common regions). Specifically, four regions included more than 50% of all reported abnormal genetic abnormalities. Moreover, a limited set of common abnormal regions comprisedthe most recurrent genetic abnormalities. Indeed, more than 95% of recurrent abnormalities were restricted to 24 common regions. A set of probes designed to cover these regions would detect all genomic abnormalities of these regions, except balanced translocation, i.e. 94.3% of all recurrent genetic abnormalities (Figure2D).
Cell culture supernatant as a DNA source to evaluate hPSC genomic integrity by ddPCR
We then decided to take advantage of this highly biased recurrence profile of hPSC genetic abnormalities to develop a rapid PCR-based approach to detect the most common recurrent abnormalities, including those that cannot be detected by karyotyping due to its resolution limits. We analyzed DNA extracted from different hPSC lines (cell-DNA) without (HY03, UHOMi001-A, iCOPD2 and iCOPD9) and with genetic abnormalities (RSP4: chromosome 20 triploidy), using ddPCR and primer pairs that target chromosome X or chromosome 20. We could observe two chromosome 20 copies in DNA samples from normal hPSC lines, and three copies in the RSP4 cell-DNA sample ( Figure 3A and S2). Second, to test the sensitivity of our approach, we prepared cell-DNA from UHOMi001-A cells (diploid line) mixed with increasing percentages (0% to 100%) of HD291 cells (chromosome 12q trisomy). Our ddPCR approach could detect the presence of the chromosome abnormality, starting from the sample containing 10% of HD291 cells ( Figure 3B ).
Another major constraint to hPSC genome integrity analysis is the need to dedicate a significant part of the cell culturefor this purpose. Therefore, we investigated whether genome integrity could be assessed using DNA extracted from the hPSCculture supernatant. We found that when using supernatant-derived DNA (supernatant-DNA), the concentration of DNA fragments, estimated by quantitative PCR (qPCR), increased progressively during hPSCs culture and was at a highest after 7 days in culture, when cell confluence was higher than 70% ( Figure 3C ). To helpelucidating the origin of the supernatant-DNA, we analyzed floating cells by staining with Annexin V and 7ADD followed by flow cytometry ( Figure 3D ). This analysis showed that 74.5% and 56.5% of floating cells were apoptotic, 12.2% and 6.6% were dead, and 13.4% and 36.9% were viable after single-cell and mechanical passaging respectively. We also measured the DNA integrity index by qPCR, using the ALU115 primers that amplify both short (apoptotic) and long (nonapoptotic) DNA fragments, and the ALU247 primers that amplify only long non-apoptotic DNA fragments (Umetani et al., 2006) . The ALU115/ALU247 ratio was higher than two, showing that supernatant contained a majority of apoptotic cells ( Figure S3 ). We also investigated the influence oftime delay before DNA extraction and freeze-thaw cycles number on the quantity of DNA extracted from cell culture supernatant samples ( Figure S3 ). These results demonstrated that stable and significant quantities of DNA can be extracted from cell culture supernatant samples.
Then, we observed an excellent agreement between the results obtained using cell-DNA and the corresponding supernatant-DNA (supernatant collected at day 5-7 of culture) ( Figure 3E ). This shows that ddPCR offers the sensitivity required for evaluating genomic integrity insupernatant-DNA, and that supernatant-DNA could be used instead of cell-DNA.
We then evaluated whether supernatant-DNA could be used to perform focused ddPCR on culture supernatant (in culture supernatant digital PCR test, iCS-digital test) using a panel of six commercial pre-designed probes that correspond to or are close to the sixmost common abnormal regions (chromosomes20q, 12, 17, X, 1 and 5). These six probes target genome regions that comprise more than 50% of all recurrent genetic abnormalities found in hPSCs (61% cumulated coverage of recurrent abnormalities).We analyzed supernatant-DNA from two hPSC lines with abnormal karyotype (HD129 and HD291: chromosome 20 and 12 triploidy, respectively) (Bai et al., 2015) and one diploid line (UHOMi001-A). The iCS-digital test results overlapped with those obtained by karyotyping ( Figure 3F ). In conclusion, targeted ddPCR can efficiently detect CNVs and can be carried out using supernatant-DNA.
Routine screening of hPSClines during cell culture and after CRISPR gene editing using the iCS-digital test
The simplicity of the iCS-digital test could allow the routine screening of the most recurrent genetic abnormalities in hPSC lines, particularly when using single-cell or small-clump passaging, a major cause of genomic alterations (Bai et al., 2015) ( Figure 1F -G). The iCS-digital test revealed that theHY03hiPSC line, which was euploid at passage 5, harbored a chromosome 1 gain at passage 15after single-cell passaging, but not after mechanical passaging ( Figure 3G ).
Cell reprogramming and genome editing using CRISPR/Cas9 require clonal expansion/selection that favors the emergence of abnormal clones. The iCSdigital test indicated no alteration at chromosomes 20q, 12, 17, X, 1 and 5 in the hiPSC line HY03 (passage M53Cl2SC11) before genome editing ( Figure   3H ). Conversely, after introduction of them Cherry cassette at the 3' of the FOXJ1 gene, or knock-out (KO) of the CCDC40gene using the CRISPR/Cas9 methodology, the iCS-digital test showed that the single clone identified to be correctly edited (passage 7) harbored a CNV of the long arm of chromosome 5 (copy number=1.3), while the four CCDC40_KO clones analyzed appeared euploid for the six regions checked ( Figure 3I ). Taken together, our results show that focused ddPCR can be used to rapidly screen iPSCs after derivation, during cell culture or amplification, and after cell cloning in settings such as gene editing.
Discussion
The present study is, to our knowledge, the largest meta-analysis of hPSC genetic abnormalities in more than 100 different research articles from many different laboratories and cell lines. This allowed us to propose a quantitative threshold to define recurrent genetic abnormalities in hPSCs and to test this threshold. Hence, a recurrent genetic abnormality is an abnormality that shares part of its abnormal sequence with other abnormalities that have been reported in at least five different publications. Our threshold should favor the detection of abnormalities that are common to different hPSC lines and different laboratories, as opposed to abnormalities that are specific to a unique cell line, a hiPSC donor cell or to the culture conditions used in one laboratory. Our analysis confirmed that CNVs are the main recurrent genetic abnormality in hPSC lines. In agreement, a recent extensive survey of NGS data to identify recurrent small mutations reported that only TP53 was prone to recurrent mutations in hPSCs (14 mutated samples among the 257 independent hPSC lines studied, 5.45%) (Merkle et al., 2017) . It has been proposed that the high hPSC susceptibility to mitotic division errors and to the upregulation of anti-apoptotic proteins contribute to the high frequency of aneuploidy and CNVs at specific genomic locations (Zhang et al., 2019) .
Indeed, we and othersidentified a limited list of genome regions that group overlapping recurrent genomic hPSC abnormalities, possibly because these changes provide a growth advantage to cultured cells. For instance, chromosome 20q11.21 gain leads to upregulation of the anti-apoptotic protein BCL-XL (Zhang et al., 2019) . Importantly, this biased distribution makes possible to study common abnormal regions by targeted PCR. For instance, by targeting only the four most common abnormal regions, more than 50% of all recurrent genetic abnormalities are covered, and more than 90% by targeting 24 regions. Screening of recurrent genetic abnormalities is paramount to claim that hPSCs are normal (Bai et al., 2013; International Stem Cell Initiative et al., 2011) . Although a targeted approach is by definition not exhaustive, it is an effective strategy to rule out the most frequent and functionally damaging abnormalities found in hPSC lines.
We demonstrated that this strategy can be carried out simply by usingDNA extracted from culture supernatant. This DNA reliably reflected the DNA profile of adherent cells. Moreover, ddPCR is a robust and sensitive technology to assess CNV on targeted abnormal genomic regions to screen the most common recurrent abnormalities.
Genomic integrity of hPSCs in culture should be frequently assessed. We recently noted in a series of 25 consecutive studies on hiPSCs that the current genomic screening practices were unsatisfactory because no genomic integrity follow-up was carried out for any of the hiPSC lines . This could be explained by the labor and costsinvolved in the implementation of classical screening techniques, such as karyotyping.
Therefore, a simple test that canrapidly rule out the most frequent recurrent genomic abnormalities might promoteadhesion to good practices for hPSC genomic integrity screening. Moreover, karyotyping can miss abnormalities that are smaller than 5 -10 Mb. For instance, we found that among all 170 recurrent genomic abnormalities on chromosome 20, 168 overlapped with 20q11.21 and among them 135 were smaller than 5 Mb. By contrast, the probes of the iCS-digital test can detect all 168 20q11.21 abnormalities.
In conclusion, we used a large dataset of hPSC genomic abnormalities based on more than 100 publications to strictly define recurrent genetic abnormalities. Our exhaustive database of such genomic defects allowed identifying a set of common abnormal genomic regions that involve more than 90% of all recurrent abnormalities. This offered the opportunity to develop and evaluate the efficacy of a targeted ddPCR approach. Moreover, we show that culture supernatant contains enough DNA to perform ddPCR. Therefore, we propose a simple test based on supernatant DNA (iCS-digital test) that could be used to routinely screencultured hPSC lines.
Experimental Procedures
Analyzing recurrence
All genetic abnormalities were converted using their GRCh37A genome coordinates. A first analysis was carried out using a recurrence score (RS) for data split in two datasets (>10 bp and ≤ 10 bp) from which polymorphic data (sequences present in dbSNP or DGV) were removed. The RS was computed by comparing each abnormality to all the others and by identifying abnormalities with a reciprocal overlap of at least 0.2. Regions with a reciprocal overlap higher than 80% were merged. For each overlap, RS was computed as follows: RS = a * s, where (a) is thenumber of abnormalitiesthat contributed to define this overlap (identicalabnormalities from the same cell line in the same study were counted only once) and (s) the number of different studies from which these overlapping abnormalities came from.
Then, to define recurrent genetic abnormalities, each abnormality >10 bp and that was not a polymorphism (n=8284 abnormalities in total) was compared with all the others, and abnormalities with a reciprocal overlap >0.33 and larger than 0,2kb, and the number of publications from which these abnormalities originated were counted. Abnormalities that overlapped with other abnormalities that came from at least four other publications (number of total publications ≥5) were defined as recurrent and kept, and this process was carried out iteratively and rapidly converged on a stable list of 738 recurrent abnormalities. Loss and gain were considered indiscriminately because the aim was to identify common abnormal regions. Bedtools was used to identify common abnormal regions.
Cell culture
The human hESC lines HD129 and HD291 were derived in our laboratory (Bai et al., 2015; Ramirez et al., 2011) 
Culture medium collection and nucleic acid extraction
Quantification of supernatant-DNA by ALU-qPCR and QuBit
Supernatant-DNA was analyzed by qPCR (LC480, Roche) using the ALU 115 and ALU 247 primers, as previously described in (Umetani et al., 2006) . One µl of each eluted supernatant-DNA sample was added to a reaction mixture containing 2X Light Cycler480 SYBR Green I master mix (Roche Applied Science, Germany) and 0.25 μ M of forward and reverse primers (ALU-115 and ALU-247) as described in (Umetani et al., 2006) 
Digital droplet PCR (ddPCR)
The ddPCR workflow was performed according the Bio-Rad instructions (Bio-Rad QX200 system). Briefly, reactions were set up using one primer pair that targets the region of interest (for instance: CNV-chr20) and a second primer pair that targets the reference gene (RPP30 
Statistical Analysis
For ddPCR, absolute quantification was based on the number of positive droplets and Poisson sampling statistics, as follows: 
Figure 2
A. Graphic representation of eight genetic abnormalities (or variants that are not polymorphic) (#1 to #8), from five different articles (A to E, one color for each article). Part or the entire sequence of seven abnormalities (in orange) overlapped and were classified as recurrent genetic abnormalities because they were from five different articles.
Conversely, abnormality #6 is not recurrent. The region shared by the seven recurrent genomic abnormalities is a common abnormal region. 
Figure S3
A concentration slightly decreased after freeze-thaw cycles applied to supernatantbefore extraction and the quality was not affected. Table   Table 1 
: Common abnormal regions
The 10 most common abnormal regions ranked according to the number (n) of abnormalities that include that region. Percentage: number of recurrent abnormalities that share a common abnormal region relative to all recurrent abnormalities (Reference genome: GRCh37/hg19). Table S1 : Articles analyzed to identify genetic abnormalities in hPSC lines.
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